No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR What Is Scanxiety? How People With Cancer and Survivors Can Cope October 28, 2021 Bagel Shop Owner Shaves Head To Support 10-Year-Old Customer October 27, 2021 When Prenatal DNA Tests Point to Cancer May 17, 2023 “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... July 20, 2020 Load more HOT NEWS Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours Dad Sings “Ave Maria” For His Daughter At Disney World EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment...
